Rare skin disease biotech eyes $16 million IPO as trial results come in and cash runs out
Armed with the first clinical results on its lead drug, a repurposed Duchenne candidate with a controversial past, and virtually no money, Processa Pharmaceuticals …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
